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Vishnoi et al Evolving Technology/Basic Sciencecisplatin, there will be a significant increase in CTCs per
tumor area and that these CTCs will be more resistant
to cisplatin. We plan to investigate our hypothesis as we
improve our ability to isolate CTCs from patients with
lung cancer.
To our knowledge, the current study is the first to show
the effect of cisplatin treatment on perfusable nodules and
the selection of cisplatin-resistant CTCs. The 4D lung
model is not likely to replace the current in vivo mouse
models, but it will provide additional information through
its ability to control many aspects of tumor growth and
development and will allow improved understanding of
the mechanisms of action of various anticancer drugs.
Ultimately, the 4D model could potentially provide an
alternative approach to study drug efficacy, mechanisms
of resistance, and molecular insights into the treatment of
non–small cell lung cancer.E
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Dr Chadrick E. Denlinger (Charleston, SC). Congratulations,
Dr Kim, on a very nice presentation of your interestingmodel. This
lung cancer model, which your group has published on previously,
is unique and potentially very important because of the limitations
inherent with traditional lung cancer cell line models. The
advantage of cell lines is that they are relatively inexpensive and
they are very reproducible, but I think some of the limitation is
that I am not sure that cancer cells grown on Petri dishes are really
representative of actual cancers in humans, and this is a point you
made in your presentation and in your manuscript.
The data presented here represent 4 different cell lines grown
in your 4D model, which leads me to my first question. Even
though you have shown here and previously that your cancer
cell lines behave differently in the rat lung scaffold compared
with standard tissue culture, how do you know they are more
representative of reality, meaning actual cancers, than standard
tissue culture?
Dr Kim.We have done several different experiments to try and
answer that question. First, if you take a cell line derived from a
cancer with a papillary phenotype and put it into our model, it
recaptures the papillary phenotype on hematoxylin and eosin.
Even though on our culture it looks like it is single cells that are
growing, in our model it kind of recaptures the pathology that
you see in a patient with lung cancer. The other thing we have
done is we compared the MMP production in a 2D versus our
4D model and the MMP production of the 4D model mimics the
production in patients with cancer. Lastly, we compared gene
expression profiles with a 4D model versus a 3D model, where
the 3D model is the cells that are grown on artificial Matrigel,
and there seems to be better correlation in terms of patient survival
with the 4D model compared with the 3D model. So there is some
evidence suggesting that this model might be better mimicked than
what we see in 2D and 3D cultures.
Dr Denlinger. Have you attempted to grow primary cancer cell
lines in your model taken directly from patients?
Dr Kim. We have attempted to grow primary cancer cells. In
order to capture this kind of biology, we need about 25 million
cells to capture in this 14-day or 21-day time period. The problem
that we are having with trying to capture from a primary tumor
from a patient is the number of cells that we can easily put into
our model. We have not been successful yet, but I think that is
one of the aims of the laboratory.
Dr Denlinger. Interesting. What you are describing as CTCs in
thismodel does sound rather analogous to cancer stem cells or cells
that have undergone epithelial-mesenchymal transition. Have you
characterized your circulating tumor cells for markers like
CD133 or CD44 that would define them as the cancer stem cells?
Dr Kim. We have not done that experiment yet. I think that is
one of the things that we are going to be looking at in future
studies. We have done some gene expression profiles, whichdiovascular Surgery c Volume 148, Number 3 1063
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in mesenchymal markers.
Dr Denlinger.You showed that your circulating tumor cells are
resistant to cisplatin. That is initially. If you continue to grow those
cells for several passages in tissue culture, do they retain their
morphology or their behavior and are cisplatin-resistant or do
they revert back to your standard H460s or H1299s?
Dr Kim. We have not done that experiment yet. I think the
CTCs that we are seeing is just a phase of this tumor development.1064 The Journal of Thoracic and Cardiovascular SurIn patients we do not really see the CTCs going back on plastic
and growing. We have not done that experiment because I am
not sure how that is going to translate exactly into patients.
What we have been trying to do is take these CTCs and put
them back into our model, thinking that it would be creating a
metastasis model and see if those metastatic lesions are more
resistant to CTCs, which would be more analogous to what is
happening in patients.
Dr Denlinger. Thank you and congratulations.gery c September 2014
